CIK 0001534120 · Non-accelerated filer<br>Smaller reporting company
Avalo Therapeutics, Inc.
Sign in to watch- Ticker
- AVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 450705648
- Phone
- 410-522-8707
- Business address
- 1500 LIBERTY RIDGE DRIVE, SUITE 321, WAYNE, PA, 19087
- Former names
- Cerecor Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,865,893
- in 5 filings, $1.9M under 10b5-1 plans
Net −$1,865,893. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-30 | Philip Ron M Director | Grant or award · Stock Option (Right to Buy) | +1,109 | $12.29 | $14K | 1,109 |
| 2026-09-30 | Jain Rita Director | Grant or award · Stock Option (Right to Buy) | +1,322 | $12.29 | $16K | 1,322 |
| 2026-09-30 | Lind Kevin Robert Director | Grant or award · Stock Option (Right to Buy) | +1,352 | $12.29 | $17K | 1,352 |
| 2026-09-16 | Sullivan Christopher Ryan Chief Financial Officer | Option exercise 10b5-1 | +12,394 | $9.88 | $122K | 52,294 |
| 2026-09-16 | Sullivan Christopher Ryan Chief Financial Officer | Sale 10b5-1 | −12,394 | $16.33 | $202K | 39,900 |
| 2026-09-16 | Sullivan Christopher Ryan Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −12,394 | 83,848 | ||
| 2026-09-10 | Sullivan Christopher Ryan Chief Financial Officer | Option exercise 10b5-1 | +10,185 | $8.04 | $82K | 50,085 |
| 2026-09-10 | Sullivan Christopher Ryan Chief Financial Officer | Sale 10b5-1 | −10,185 | $17.62 | $179K | 39,900 |
| 2026-09-10 | Sullivan Christopher Ryan Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,185 | 105,815 | ||
| 2026-08-28 | Doyle Mittie Chief Medical Officer | Option exercise 10b5-1 | +679 | $8.04 | $5K | 52,455 |
| 2026-08-28 | Doyle Mittie Chief Medical Officer | Sale 10b5-1 | −679 | $20.00 | $14K | 51,776 |
| 2026-08-28 | Doyle Mittie Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −679 | 113,734 | ||
| 2026-08-18 | Sullivan Christopher Ryan Chief Financial Officer | Option exercise 10b5-1 | +31,031 | $9.88 | $307K | 70,931 |
| 2026-08-18 | Sullivan Christopher Ryan Chief Financial Officer | Sale 10b5-1 | −31,031 | $20.05 | $622K | 39,900 |
| 2026-08-18 | Sullivan Christopher Ryan Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −31,031 | 96,242 | ||
| 2026-08-17 | Doyle Mittie Chief Medical Officer | Option exercise 10b5-1 | +1,000 | $12.65 | $13K | 52,776 |
| 2026-08-17 | Doyle Mittie Chief Medical Officer | Sale 10b5-1 | −1,000 | $20.00 | $20K | 51,776 |
| 2026-08-17 | Doyle Mittie Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,000 | 123,750 | ||
| 2026-08-17 | Sullivan Christopher Ryan Chief Financial Officer | Option exercise 10b5-1 | +37,945 | $9.88 | $375K | 78,718 |
| 2026-08-17 | Sullivan Christopher Ryan Chief Financial Officer | Option exercise 10b5-1 | +2,876 | $9.88 | $28K | 81,594 |
Page 1 of 11 · 202 trades